Dr. Steven Marso, MD

Dr. Steven Marso, MD

CardiologyMaleAge 54

Accepting new patients

Dr. Steven Marso, MD is a Cardiology Specialist in Overland Park, KS. He is affiliated with medical facilities such as Overland Park Regional Medical Center and Centerpoint Medical Center. He is accepting new patients and has indicated that he accepts telehealth appointments. Be sure to call ahead with Dr. Marso to book an appointment.

Locations

Midwest Heart & Vascular Associates - Overland Park

Overland Park5100 W 110th St Ste 200 Fl 2 Overland Park, KS 66211
1

Hospital Highlight

Affiliated with Centerpoint Medical Center Independence, a highly rated hospital.

At a Glance

  • Explains Conditions Well Patients said this doctor explains conditions well. See reviews
  • Offers Telehealth This provider offers telehealth appointments. Call the office to schedule an appointment.
  • Practices at Top Hospital America’s 100 Best Hospitals for Cardiac Care Award™ See hospitals

More Cardiology Specialists at Centerpoint Medical Center

Dr. Marso's Reviews

Likelihood to recommend Dr. Marso

5.0

Based on 12 ratings

5 Stars
100%
(12)
4 Stars
0%
(0)
3 Stars
0%
(0)
2 Stars
0%
(0)
1 Star
0%
(0)
healthgrades logo

Leave a review

How likely are you to recommend
Dr. Marso
(Select your rating)
What went well
No reviews yet
What could be improved
No reviews yet
RecentHighestLowestMost Helpful
Reply
I was very impressed with Dr. Marso upon my first visit... he listened intently and explained My condition in terms that I could understand
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Wait times
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
Dennis Leisenring in Springfield , MO – Apr 09, 2019
×Post a ResponseAre you Dr. Steven Marso, MD?
Reply
I've know Dr. Marso for several years. He has been extremely helpful and caring to my family and extended family. When it was time for me to contact a Heart Specialist there was no one else to consider.
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Wait times
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
John Gilman in Overland Park, KS – Jan 27, 2019
×Post a ResponseAre you Dr. Steven Marso, MD?
Reply
Prompt; I got in right away and hardly waited at all (rare!). All the staff was very friendly.
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Wait times
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
BJ in Prairie Village, KS – Dec 24, 2018
×Post a ResponseAre you Dr. Steven Marso, MD?
Reply
DR. MARSO IS OUTSTANDING; EXPLAINS THINGS SO YOU UNDERSTAND THEM . ANSWERS ALL QUESTIONS YOU HAVE .
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Wait times
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
BILL HAPES in CHILLICOTHE , MO – Aug 08, 2018
×Post a ResponseAre you Dr. Steven Marso, MD?
Reply
I have had and presently have several doctors for various problems, ie. Urologist, General care, eye doctor for vision problems...but the foremost important doctor to me is my cardiologist. Dr. Marso is by far the best I have had the experience in my 74+ years. He truly takes the time to listen , really listen. I am blessed for having a wonderful Christian doctor in Dr. Steven Marso.
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
Lou Bacco in Shawnee, KS – Jul 23, 2018
×Post a ResponseAre you Dr. Steven Marso, MD?
Reply
Dr. Marso was very professional and personable. He listened to my concerns, and took time to answer my questions so that I fully understood. I never felt hurried or rushed. I would definitely recommend Dr. Marso and this office.
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Wait times
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
Jodi in Overland Park, KS – Apr 10, 2018
×Post a ResponseAre you Dr. Steven Marso, MD?
Reply
Dr. Marso is a fine doctor and is very patient and kind and explains things when you ask. I highly recommend him to others when opportunity arises. I was impressed after my second visit. Thank you Dr. Marso!
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Wait times
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
Stephen in Overland Park,Kansas – Apr 04, 2018
×Post a ResponseAre you Dr. Steven Marso, MD?
Reply
Very good. Highly recommended.
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Wait times
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
Donald Rogers in Lenexa, ks. – Apr 02, 2018
×Post a ResponseAre you Dr. Steven Marso, MD?
Reply
Dr Marso is a great down to earth doctor and explains everything to you so you will understand. I see that he puts his patients health as a priority and gives them the best care! Being my first ever visit to a cardiologist and I believe I was referred to one of the best!
What went well
  • Appointment scheduling
  • Office environment
  • Staff friendliness
  • Wait times
  • Appointment wasn't rushed
  • Listened & answered questions
  • Explained conditions well
  • Trusted the provider's decisions
What could be improved
No results
Helpful
Mike in Belton, MO – Sep 22, 2017
×Post a ResponseAre you Dr. Steven Marso, MD?

Leave a review

How was your experience with Dr. Marso?

Experience and Background Checks

Experience
Background

Background Check

Healthgrades does not collect malpractice claims information for Kansas
No disciplinary actions found for the years we collect data
No board actions found for the years we collect data
Learn more about background checks

Experience Check

Check Dr. Marso's experience treating your condition or procedure

Dr. Marso's Top Procedures and Conditions

Treatment Frequency
Electrocardiogram (EKG)
high
high

Treatment Frequency

Dr. Marso performs Electrocardiogram (EKG) more than 93% of his peers

Dr. Marso performs this procedure more than 93% of his peers

Heart Disease
high
high

Treatment Frequency

Dr. Marso treats Heart Disease more than 93% of his peers

Dr. Marso treats this condition more than 93% of his peers

Heart Palpitations
high
high

Treatment Frequency

Dr. Marso treats Heart Palpitations more than 90% of his peers

Dr. Marso treats this condition more than 90% of his peers

Dr. Marso's conditions and procedures:

  • Aneurysm
  • Aneurysm of Heart
  • Angina
  • Angina and Acute Coronary Syndrome
  • Aortic Aneurysm
  • Aortic Dissection
  • Aortic Ectasia
  • Aortic Stenosis
  • Aortic Valve Disease
  • Aortic Valve Regurgitation
  • Arrhythmia Screening
  • Arrhythmias
  • Atrial Fibrillation
  • Atrial Flutter
  • Atrial Septal Defect
  • Automatic Implantable Cardioverter Defibrillator (ICD) Implantation
  • Cardiac Catheterization (incl. Coronary Angiography)
  • Cardiac Imaging
  • Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
  • Cardiac Myocardial Perfusion Imaging
  • Cardiac Tamponade
  • Cardiomegaly
  • Cardiomyopathy
  • Cardiomyopathy, Dilated
  • Cardiomyopathy, Hypertrophic
  • Cardiovascular Diagnostic Test
  • Cardiovascular Stress Test
  • Cardioversion, Elective
  • Cardioverter-Defibrillator or Pacemaker Insertion, Removal or Repair
  • Carotid Artery Disease
  • Chest CT (incl. Heart and Lungs)
  • Chest Pain
  • Chest Pain Evaluation
  • Cholesterol Screening
  • Chronic Pulmonary Heart Diseases (incl. Pulmonary Hypertension)
  • Coarctation of the Aorta
  • Congenital Aortic Valve Disorders
  • Congenital Heart Defects
  • Congenital Heart Disease
  • Congestive Heart Failure
  • Coronary Angiogram
  • Coronary Angioplasty, Atherectomy and Stent
  • Coronary Artery Disease (CAD)
  • Coronary Artery Dissection
  • Coronary Cathertization With Robotic Assistance
  • Dobutamine Thallium Stress Test
  • Echocardiography
  • Electrocardiogram (EKG)
  • Endocarditis
  • First Degree Heart Block
  • Heart Attack (Acute Myocardial Infarction)
  • Heart Disease
  • Heart Murmur
  • Heart Palpitations
  • HeartAware Online Risk Screening
  • Hyperlipidemia
  • Hypertension
  • Hypertensive Chronic Kidney Disease
  • Hypertensive Heart and Chronic Kidney Disease
  • Hypertensive Heart Disease
  • Hypotension
  • Impella Device
  • Kawasaki Disease
  • Limb Swelling Caused by Fluid Overload
  • Marfan Syndrome
  • Mitral Valve Disease
  • Mitral Valve Prolapse
  • Mitral Valve Regurgitation
  • Mitral Valve Stenosis
  • Mobitz, Type 2, Heart Block
  • Non-Coronary Angioplasty, Atherectomy, and Stenting
  • Nuclear Stress Testing
  • Pacemaker Insertion or Replacement
  • Patent Foramen Ovale (PFO)
  • Pericardial Disease
  • Pericarditis
  • Peripartum Cardiomyopathy
  • Peripheral Arterial Disease Screening (PAD)
  • Peripheral Artery Catheterization
  • Pharmacologic Nuclear Stress Test
  • Pharmacologic Stress Test, Adenosine
  • Primary Pulmonary Hypertension
  • Pulmonary Edema
  • Pulmonary Hypertension
  • Pulmonary Valve Disease
  • Removal or Revision of Pacemaker or Cardioverter and-or Defibrillator
  • Second Degree Heart Block
  • Secondary Hypertension
  • Septal Defect
  • Sick Sinus Syndrome
  • Sinus Bradycardia
  • Sinus Tachycardia
  • Stress Test
  • Structural Heart Disease Evaluations and Treatment
  • Supraventricular Tachycardia
  • Syncope
  • Systemic Vasculitis
  • TCD Bubble Test
  • Third Degree Heart Block
  • Thrombolysis
  • Tilt Table Testing
  • Tilt Testing or Cardiac Event Monitors
  • Treadmill Stress Test
  • Tricuspid Valve Disease
  • Unstable Angina
  • Vascular Duplex Ultrasonography and Plethysmography
  • Ventricular Fibrillation
  • Ventricular Septal Defect
  • Ventricular Tachycardia (VT)
  • Wolff-Parkinson-White Pattern

Insurance Check

Search for your insurance provider

Dr. Marso accepts

Accepted insurance can change. Please double-check when making an appointment.

(913) 386-2955

Dr. Marso accepts the following insurance:

Aetna
Aetna HMO
Choice Plus POS II
Anthem Blue Cross Blue Shield
Anthem Blue Cross Blue Shield PPO
Blue Preferred Plus POS
Blue Cross Blue Shield
Blue Card PPO
Cigna
Cigna HMO
Cigna PPO
Open Access Plus
First Health (Coventry Health Care)
First Health (Coventry Health Care) PPO
Humana
Choice Care PPO
Preferred PPO
MultiPlan
MultiPlan PPO

About Me

Biography

This physician is accepting telehealth visits. Steven P. Marso, MD, is chief medical officer for HCA Midwest Health cardiovascular services. With more...Read more

Specialties

  • Cardiology
  • Interventional Cardiology

Board Certifications

  • Interventional Cardiology

Education

Mid America Heart Institute | Cleveland Clinic Foundation | Cleveland Clinic Foundation
Fellowship Hospital
University of Virginia Medical Center
Residency Hospital
University of Kansas Medical Center School of Med
Medical School

Awards

Media & Publications

  • Coronary plaque dimensions and composition by intravascular ultrasound radio frequency lesion segment analysis in stable and unstable angina patients,
  • Fractional Flow Reserve and Intravascular Ultrasound RelationShip Study: The FIRST Study,
  • Percutaneous transluminal angioplasty: association between depressive symptoms and diminished health status benefits,
  • The Pathogenesis of Type 2 Diabetes and Cardiovascular Disease,
  • Proteinuria is a Key Determinant of Death in Patients with Diabetes After Isolated Coronary Bypass Grafting,
  • Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With-vs-Without Diabetes Mellitus from the EMERALD Tria,
  • Characteristics and clinical significance of angiographically mild lesions in acute coronary syndromes,
  • Diabetes, Obesity and Metabolism - Manuscript,
  • The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis,
  • Evaluating the Benefits of GP IIb/IIIa Inhibitors in Heart Failure at Baseline in Acute Coronary Syndromes,
  • Atherosclerotic Plaque Composition and Clinical Outcomes in patients with Acute Coronary Syndromes and Metabolic Syndrome or Diabetes: Analysis from the PROSPECT study,
  • Vulnerable plaque intervention: State of the Art,
  • Quantifying Improvement in Symptoms, Functioning and Quality of Life Following Peripheral Endovascular Revascularization,
  • The frequency of vascular complications associated with the use of vascular closure devices varies by indication for cardiac catheterization,
  • Transparency of Appropriateness Criteria,
  • Success rates of percutaneous coronary intervention of chronic total occlusions and long-term survival in patients with diabetes mellitus,
  • Diabetes and Percutaneous Coronary Intervention in the Setting of an Acute Coronary Syndrome,
  • Intracoronary Stenting: an Overview for the Clinician,
  • Drug Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients with Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization: Analysis from the National Cardiovascular Data Registry,
  • Procedural Outcomes and Long-Term Survival Among Patients Undergoing Percutaneous Coronary Intervention of a Chronic Total Occlusion in Native Coronary Arteries: A 20-Year Experience,
  • Long-Term Survival and Procedural Success in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention of a Chronic Total Occlusion,
  • Relationship between Baseline Inflammatory Markers, Antiplatelet Therapy and Adverse Cardiac Events Following Percutaneous Coronary Intervention: An Analysis from the CREDO Trial,
  • LEADER 3-Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Tria,
  • Incidence, Correlates and Outcomes of Acute, Hospitalacquired Anemia in Patients with Acute Myocardial Infarction.,
  • Multivessel Percutaneous Coronary Intervention In Patients with Multivessel Disease and Acute Myocardial Infarction,
  • The Paradoxical Benefit of Sulfonylurea Agents in Diabetics Undergoing Coronary Revascularization,
  • Compensatory enlargement of the left main coronary artery: insights from the PROSPECT study,
  • Predicting restenosis in drug eluting stents placed in real-world clinical practice: Derivation and validation of a risk model from the EVENT registry,
  • Diabetes and Drug Eluting Stents: What You Get and What You Don't (Editorial Comment),
  • Neointimal Hyperplasia Following Arterial Injury is Increased in a Rat Model of Non-Insulin-Dependent Diabetes Mellitus,
  • .Relationship between paplography and virtual histology in patients with acute coronary syndromes,
  • Acute coronary syndrome in the patient with diabetes: is the management different?,
  • Blood Transfusion During Acute Myocardial Infarction – Association With Mortality and Variability Across Hospitals,
  • Relation of Hemoglobin A1C to Left Ventricular Relaxation in Patients with Type 1 Diabetes Mellitus without Overt Heart Disease: A Tissue Doppler Echocardiographic Study,
  • Tissue characterisation of atherosclerotic plaque in the left main: an in vivo intravascular ultrasound radiofrequency data analysis,
  • Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes. A Meta-Analysis of Randomized Clinical Trials,
  • Prospective Natural History Study of Coronary Atherosclerosis using Multimodality Intravascular Imaging,
  • Prognostic Implications of Creatine Kinase-MB Elevation after Percutaneous Coronary Intervention,
  • Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intrvention: analysis from the National Cardiovascular Data Registry,
  • Central Role of RAGE-Dependent Neointimal Expansion in Arterial Restenosis,
  • Cost-Effectiveness of Targeting Patients Undergoing PCI for Therapy with Bivalirudin vs. Heparin Monotherapy According to Predicted Risk of Bleeding,
  • Relation between Angio graphic Lesion Severity, Vulnerable Plaque Morphology and Future Adverse Cardiac Events in the Coronary Tree Study,
  • Peripheral Arterial Disease in Patients with Diabetes,
  • Tissue Characterization of Atherosclerotic Plaque in the Left Main: An Intravascular Ultrasound Radiofrequency Data Analysis in Humans,
  • Catheter-Based Reperfusion Of Unprotected Left Main Stenosis During an Acute Myocardial Infarction (the ULTIMA Experience) Unprotected Left Main Trunk Intervention Multi-Center Assessment,
  • Procedural Outcomes and Long-Term Survival Among Patients Undergoing Percutaneous Coronary Intervention of a Chronic Total Occlusion inactive Coronary Arteries: A 20-Year Experience,
  • Low Adiponectin Levels are Associated with Atherogenic Dyslipidemia and Lipid-Rich Plaque in Non-Diabetic Coronary Arteries.,
  • The editor's roundtable: intravascular ultrasonic imaging of the coronary arteries,
  • Increase in interleukin-6 following arterial injury is related to insulin resistance, the -174G-->C polymorphism and complex plaque morphology,
  • Incomplete Stent Apposition: Should we Appose or Oppose?,
  • Insulin Resistance and Novel Markers of Cardiovascular Disease in Type 2 Diabetes,
  • Immediate Coronary Artery Bypass Surgery After Platelet Inhibition with Eptifibatide: Results from PURSUIT,
  • Optimizing the Diabetic Formulary: Beyond Aspirin and Insulin,
  • Intravascular ultrasound radiofrequency analysis of coronary atherosclerosis: an emerging technology for the assessment of vulnerable plaque,
  • Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury,
  • Enhanced Efficacy of Eptifibatide Administration in Patients with Acute Coronary Syndrome Requiring In-Hospital Coronary Artery Bypass Grafting,
  • An Intravascular Ultrasound Appraisal of Atherosclerotic Plaque distribution in Diseased Coronary Arteries,
  • A Comparison of the Recovery of Health Status after Percutaneous Coronary Intervention and Coronary Artery Bypass,
  • Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes,
  • Design of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,
  • Mode of Death After Contemporary Percutaneous Coronary Intervention: A Report from the Evaluation of Drug Eluting Stents and Ischemic Events,
  • Dies clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study,
  • Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease,
  • Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2–3 liraglutide clinical development studies,
  • Diabetes mellitus: Biological Determinants of Atherosclerosis and Restenosis,
  • Plaque burden with composition? That is the next question,
  • Do Systemic Risk Factors Impact Invasive Findings from Virtual Histology? Insights from the International Virtual Histology Registry,
  • Comparison of Bleeding Complications Using Arterial Closure Device versus Manual Compression by Propensity Matching in Patients Undergoing Percutaneous Coronary Intervention,
  • Improving In-Hospital Mortality in the Setting of an Increasing Risk Profile among Patients Undergoing Catheter-Based Reperfusion for an Acute Myocardial Infarction without Cardiogenic Shock,
  • Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention,
  • Amplified Benefit of Clopidogrel versus Aspirin in Patients with a History of Diabetes Mellitus,
  • Myonecrosis following Isolated Coronary Artery Bypass Grafting is Common and Associated with an Increased Risk of Long-term Mortality,
  • Revascularization trumps medicine for patients with type 2 diabetes mellitus and chronic angina (or does it?),
  • Outcomes of Patients with Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting: Results from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial,
  • Comparison of Costs Between Transradial and Transfemoral Percutaneous Coronary Intervention: A Cohort Analysis from the Nationwide Premier Perspective Hospital Database,
  • Outcomes of 1090 Consecutive Elective, Non-selected, Percutaneous Coronary Interventions at a Community Hospital without Onsite Cardiac Surgery,
  • Percutaneous coronary intervention use in the United States: defining measures of appropriateness,
  • Limitations to the use of virtual histologyintravascular ultrasound to detect vulnerable plaque,
  • Preprocedural estimate of individualized bleeding risk impact physicians’ utilization of bivalirudin during percutaneous coronary intervention,
  • Diabetes Mellitus is Associated with Plaque Classified as Thin Cap Fibroatheroma: An Intravascular Ultrasound Study,
  • Stratification of risk in thin cap fibroatheromas using peak plaque stress estimates from idealized finite element models,
  • Steatosis and Diastolic Dysfunction: The Skinny on Myocardial Fat,
  • LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.,
  • The Prevalence and Outcomes of Transradial Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: Analysis from the NCDR®,
  • Rapid Adoption of Drug Eluting Stents: Clinical Practices and Outcomes from the Early DES Era,
  • Suitability of Saphenous Vein Graft Lesions for the Use of Distal Embolic Protection,
  • Metabolic Syndrome-Mediated Inflammation following Elective Percutaneous Coronary Intervention,
  • Optimizing Percutaneous Coronary Revascularization in Diabetic Women: Analysis from the EPISTENT Trial,
  • Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus,
  • Percutaneous Intervention of Circumflex Chronic Total Occlusions Is Associated With Worse Procedural Outcomes: Insights From a Multicentre US Registry,
  • Optimizing the Percutaneous Interventional Outcomes for Patients with Diabetes Mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy,
  • State of the Art: Chronic Total Occlusion Angioplasty in the United States,
  • Diabetes Mellitus and Vascular Risk: Continuing the Quest for the Elusive Keystone,
  • Risk of Restenosis and Health Status Outcomes for Patients Undergoing PCI Vs. CABG Surgery,
  • Temporal Trends in and Factors Associated with Bleeding Complications among patients Undergoing Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data CathPCI Registry,
  • The Impact of Bivalirudin and Vascular Closure Device Use on Percutaneous Coronary Intervention-Related Bleeding,
  • What is the Optimal Threshold for Defining a Periprocedural Myocardial Infarction? Prognostic Implications of Creatine Kinase-MB Elevation after Percutaneous Coronary Intervention,
  • Improving the Pharmacological Regimen for People with Diabetes Mellitus,
  • Coronary Revascularization Strategies in Patients With Diabetes and Multivessel Coronary Artery Disease: Has the Final Chapter Been Written?,
  • Costs of Transradial Percutaneous Coronary Intervention,
  • Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study,
  • Diabetes and Percutaneous Coronary Revascularization in the DrugEluting,
  • Excimer laser atherectomy to overcome intraprocedural obstacles in chronic total occlusion percutaneous intervention: Case examples,
  • Diabetes Mellitus is Associated with a Shift in the Temporal Risk Profile In-Hospital Death after Percutaneous Coronary Intervention: An Analysis of 25,223 Patients Over 20 Years,
  • Diabetes Duration is Associated with Increased Thin Cap Fibroatheroma,
  • Association between Bleeding Events and IN-hospital Mortality following Percutaneous Coronary Intervention,
  • An Invasive Strategy is Associated with Decreased Mortality in Patients with Unstable Angina and NonST-Elevation Myocardial Infarction: GUSTO IIb Tria,
  • Association between Use of Bleeding Avoidance Strategies and Risk of Periprocedural Bleeding Among Patients Undergoing Percutaneous Coronary Intervention,
  • Utilization of Distal Embolic Protection in Saphenous Vein Graft Interventions (An Analysis of 19,546 Patients in the American College of Cardiology – National Cardiovascular Data Registry),
  • The Importance of Proteinuria as a Determinant of Mortality Following Percutaneous Coronary Revascularization in Diabetics,
  • Intravascular Ultrasound Measures of Coronary Atherosclerosis and Estimates of Future Cardiovascular Risk Using the Framingham Risk Score: An Analysis from a Global IVUS Registry,
  • Comparative Effectiveness of Drug-Eluting Versus Bare-Metal Stents in Elderly Patients Undergoing Revascularization of Chronic Total Coronary Occlusions,
  • Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk,
  • Suspected Acute Coronary Syndrome Patients With Diabetes and Normal Troponin-I Levels Are at Risk for Early and Late Death: Identification of a new high-risk acute coronary syndrome population,
  • Chest Pain – A Strong Predictor of Adverse Cardiac Events Following Percutaneous Intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial,
  • Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound,
  • Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit,
  • Does Proteinuria Predict Mortality After Percutaneous Revascularization in Diabetics?,
  • Carotid Artery Stenting in the Setting of a Contralateral Carotid Artery Occlusion: Results from the Carotid Artery Revascularization and Endarterectomy (CARE) Registry,
  • Abciximab Reduces Mortality in Diabetics Following Percutaneous Coronary Intervention,
  • Comparison of procedural complications with versus without interventional cardiology fellows-in-training during contemporary percutaneous coronary intervention,
  • Effectiveness of Percutaneous Coronary Interventions to Prevent Recurrent Coronary Events in Patients on Chronic Hemodialysis,
  • Procedural Failure of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from a Multicenter US Registry,
  • Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm from the National Cardiovascular Data Registry,
  • Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity,
  • Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A PropensityMatched Study,
  • Revascularizing Chronic Total Occlusions: What About the Coronary Collaterals and Myocardial Viability Story?,
  • Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction after Percutaneous Coronary Intervention in Unselected Patients: Results from the EVENT Registry,
  • Improvement in Survival Following Successful Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions: Variability by Target Vessel,
Less...

Frequently Asked Questions

How can I make an appointment with Dr. Steven Marso, MD?

Call (913) 346-2815 to make an appointment as a new patient. Click here for more information.

Does Dr. Steven Marso, MD offer telehealth services?

Dr. Marso has indicated that they offer telehealth. Contact the office to check for eligibility for your needs.

Is Dr. Steven Marso, MD accepting new patients?

Dr. Steven Marso, MD generally accepts new patients on Healthgrades. You can see Dr. Marso's profile to make an appointment.

Does Dr. Steven Marso, MD accept my insurance?

Use the Healthgrades insurance check to verify if Dr. Marso accepts your insurance.

What are Dr. Steven Marso, MD's top areas of care?

Dr. Marso frequently treats Electrocardiogram (EKG), Heart Disease, and Heart Palpitations. See all procedures and conditions Dr. Marso treats.

Where is Dr. Steven Marso, MD's office located?

Dr. Marso's office is located at 5100 W 110th St Ste 200 Fl 2, Overland Park, KS 66211. Find other locations and directions on Healthgrades.

Affiliated Hospitals

Dr. Marso is affiliated with the following hospitals. Select a hospital below to learn more.

Learn more about how Healthgrades measuresHospital Quality.

Overland Park Regional Medical Center

Overland Park, KS

74% Patient Experience Rating, 5% higher than the national average

Centerpoint Medical Center

Independence, MO

70% Patient Experience Rating, 1% higher than the national average

17 Awards Received

Award Highlight: Patient Safety Excellence Award™ (2021)

Research Medical Center

Kansas City, MO

65% Patient Experience Rating, 4% lower than the national average

3 Awards Received

Award Highlight: Patient Safety Excellence Award™ (2021)

Saint Luke's Hospital of Kansas City

Kansas City, MO

81% Patient Experience Rating, 12% higher than the national average

20 Awards Received

Award Highlight: Coronary Intervention Excellence Award™ (2021)